- Home
- FHTX vs TVA Comparison
FHTX vs TVA Comparison
Compare FHTX & TVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHTX
- TVA
- Stock Information
- Founded
- FHTX 2015
- TVA 2024
- Country
- FHTX United States
- TVA United States
- Employees
- FHTX N/A
- TVA N/A
- Industry
- FHTX Medicinal Chemicals and Botanical Products
- TVA
- Sector
- FHTX Health Care
- TVA
- Exchange
- FHTX Nasdaq
- TVA Nasdaq
- Market Cap
- FHTX 278.1M
- TVA 303.9M
- IPO Year
- FHTX 2020
- TVA 2025
- Fundamental
- Price
- FHTX $4.23
- TVA $11.02
- Analyst Decision
- FHTX Strong Buy
- TVA
- Analyst Count
- FHTX 5
- TVA 0
- Target Price
- FHTX $11.80
- TVA N/A
- AVG Volume (30 Days)
- FHTX 270.7K
- TVA 445.1K
- Earning Date
- FHTX 10-31-2025
- TVA 01-01-0001
- Dividend Yield
- FHTX N/A
- TVA N/A
- EPS Growth
- FHTX N/A
- TVA N/A
- EPS
- FHTX N/A
- TVA N/A
- Revenue
- FHTX $24,173,000.00
- TVA N/A
- Revenue This Year
- FHTX $42.43
- TVA N/A
- Revenue Next Year
- FHTX $14.77
- TVA N/A
- P/E Ratio
- FHTX N/A
- TVA N/A
- Revenue Growth
- FHTX N/A
- TVA N/A
- 52 Week Low
- FHTX $2.95
- TVA $9.98
- 52 Week High
- FHTX $9.70
- TVA $12.27
- Technical
- Relative Strength Index (RSI)
- FHTX 45.28
- TVA N/A
- Support Level
- FHTX $3.85
- TVA N/A
- Resistance Level
- FHTX $4.69
- TVA N/A
- Average True Range (ATR)
- FHTX 0.33
- TVA 0.00
- MACD
- FHTX 0.04
- TVA 0.00
- Stochastic Oscillator
- FHTX 55.77
- TVA 0.00
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
About TVA Texas Ventures Acquisition III Corp Class A Ordinary Share
Texas Ventures Acquisition III Corp is a blank check company.